Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC.

  • 2026-01
  • The New England journal of medicine 394(1)
    • Wenfeng Fang
    • Lin Wu
    • Xiangjiao Meng
    • Yu Yao
    • Wei Zuo
    • Wenxiu Yao
    • Yanyan Xie
    • Yu Zhang
    • Jiuwei Cui
    • Yongchang Zhang
    • Xingya Li
    • Wu Zhuang
    • Jian Fang
    • Qiming Wang
    • Wei Jiang
    • Kai Li
    • Yuju Bai
    • Yongzhong Luo
    • Fang Ma
    • Yan Yu
    • Wei Zheng
    • Zhentian Liu
    • Bin Yang
    • Rui Ma
    • Yong Fang
    • Runxiang Yang
    • Liyan Jiang
    • Jie Hu
    • Jiacheng Yang
    • Yina Diao
    • Xiaoping Jin
    • Junyou Ge
    • Yunpeng Yang
    • Li Zhang

Study Design

Type
Randomized Controlled Trial (RCT)
Sample size
n = 376
Population
patients with EGFR-mutated locally advanced or metastatic nonsquamous NSCLC that had progressed after EGFR-TKI therapy
Methods
phase 3 trial, patients randomly assigned in a 1:1 ratio to receive sac-TMT monotherapy or pemetrexed plus platinum-based chemotherapy
Blinding
Double-blind
Duration
median follow-up of 18.9 months
Funding
Industry-funded
  • Large Human Trial

Background

Sacituzumab tirumotecan (sac-TMT) is an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 that has shown significant survival benefits in patients with EGFR-mutated non-small-cell lung cancer (NSCLC) that has progressed after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy.

Methods

In this phase 3 trial, we enrolled patients with EGFR-mutated locally advanced or metastatic nonsquamous NSCLC that had progressed after EGFR-TKI therapy. The patients were randomly assigned, in a 1:1 ratio, to receive sac-TMT monotherapy or pemetrexed plus platinum-based chemotherapy. The primary end point was progression-free survival as assessed by blinded independent review. Overall survival was a hierarchically tested key secondary end point. In the interim analysis of progression-free survival as assessed by blinded independent review, sac-TMT monotherapy met the prespecified criterion for significance (two-sided P<0.0001); we report here the prespecified final analysis of progression-free survival and the preplanned interim analysis of overall survival.

Results

Overall, 376 patients underwent randomization, with 188 assigned to each group. After a median follow-up of 18.9 months, the median progression-free survival was 8.3 months in the sac-TMT group and 4.3 months in the chemotherapy group (hazard ratio for disease progression or death, 0.49; 95% confidence interval [CI], 0.39 to 0.62). Overall survival was significantly longer with sac-TMT than with chemotherapy (hazard ratio for death, 0.60; 95% CI, 0.44 to 0.82; two-sided P = 0.001); 18-month overall survival was 65.8% and 48.0%, respectively. Treatment-related adverse events of grade 3 or higher occurred in 58.0% of patients receiving sac-TMT and in 53.8% of those receiving chemotherapy, with the most common being a decreased neutrophil count (39.9% vs. 33.0%); treatment-related serious adverse events occurred in 9.0% and 17.6%, respectively.

Conclusions

In patients with EGFR-mutated advanced or metastatic NSCLC that had progressed after previous EGFR-TKI therapy, progression-free survival and overall survival outcomes were significantly better with sac-TMT than with platinum-based chemotherapy. (Funded by Sichuan Kelun-Biotech Biopharmaceutical; OptiTROP-Lung04 ClinicalTrials.gov number, NCT05870319.).

Research Insights

    Back to top